Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NI-1801 Monotherapy and Combination in Advanced MSLN-Expressing Solid Tumors
NCT05403554Phase 1Recruiting
- Sponsor
- Lightchain Bioscience
- Start
- Apr 2022
- Primary completion
- May 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of NI-1801 in epithelial ovarian cancer (EOC), triple-negative breast cancer (TNBC), Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) and 1 more (4 arms), sponsored by Lightchain Bioscience. Primary endpoints: Dose Limiting Toxicity at 12 months, Non-Tolerated Dose at 12 months and 3 more. Started Apr 2022; status: recruiting.
02
Drugs
NI-1801
03
Conditions
epithelial ovarian cancer (EOC)triple-negative breast cancer (TNBC)Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05403554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05403554.